ASX:CU6Pharmaceuticals
Clarity Pharmaceuticals (ASX:CU6): Evaluating Valuation Following Breakthrough Co-PSMA Trial Results
Clarity Pharmaceuticals (ASX:CU6) has reported that its Co-PSMA trial achieved a key milestone, showing that 64Cu-SAR-bisPSMA identifies significantly more prostate cancer lesions compared to current standard imaging in patients with low PSA levels.
See our latest analysis for Clarity Pharmaceuticals.
Clarity’s latest clinical achievement has reignited interest, helping the stock stage a strong rebound. The 30-day share price return sits at an impressive 41.0%, though shares are still down...